Mode
Text Size
Log in / Sign up
Phase 3 N=58 Randomized Quadruple-blind Treatment

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

Gastroparesis

Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Dec 2012
Primary outcome: Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Gastric Electrical Stimulator, Enterra, Medtronics, Inc. (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Mississippi Medical Center
Primary completion
Oct 2006

Outcome Measures

OutcomeResultp-value
PRIMARY
Symptom of Vomiting Associated With Gastroparesis
1.82; 2.68; 0.17; 1.20; 0.91; 0.72
PRIMARY
Symptom of Nausea Associated With Gastroparesis
3.27; 3.33; 1.46; 1.67; 2.26; 1.4
PRIMARY
Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis
67.07; 66.13; 69.96; 37.41; 64.71; 16.43

Summary

The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying). We hypothesize that when the device is ON, Gastrointestinal symptoms will decrease by at least 50% from baseline.

Eligibility Criteria

Inclusion Criteria

  • Sex: Male of Female
  • Age Range: 18 to 70 inclusive
  • Patients with GP of diabetic, surgically related or idiopathic etiology.
  • Symptoms of GP for >/= 1 year.
  • Refractory or intolerant to antiemetic drug classes (antihistamines and phenothiazines, serotonin receptor antagonists, dopamine receptor antagonists)
  • Chronic vomiting and/or nausea with 7 or more episodes per week for either symptom irrespective of GET values.
  • The patient is willing and able to provide informed consent.
  • The patient is willing and able to return for required follow-up visits.

Exclusion Criteria

  • Patients 70 years in age.
  • Patients with an active infection of any kind.
  • Patients who the investigator determines are not candidates for endoscopic procedures.
  • Women who are pregnant
  • Inability or unwillingness to provide informed consent
  • Unwilling or unable to return for required follow-up visits and examinations.
  • Patients who are currently enrolled in another investigation of a medical device or drug.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00432835). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search